drugset / Trial / NCT05899764

Epileptic Hippocampus in Alzheimer's Disease

NCT05899764

Phase 1/2 Not yet recruiting 25 enrolled University of California, Los Angeles
NaSingle-groupOpen-labelTreatment

Summary

The major goals of the study are to 1) characterize hippocampal activity in patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and AD who have suspected hippocampal epileptic activity based on scalp EEG recordings from IRB # 21-001603; 2) study the efficacy of brivaracetam to suppress epileptic activity and pathological high frequency oscilations (pHFOs) during hippocampal depth electrode and scalp EEG in patients with MCI and AD; and 3) investigate the effects of brivaracetam on cognition in an open-label pilot study.

Timeline

Start
2026-01-01
Primary completion
2029-06-01
Completion
2029-06-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Brivaracetam Small molecule 25 mg Intravenous
Subject Brivaracetam Small molecule 50 mg Intravenous